Florica POPESCU *, F. D. POPESCU **, L. Ghilencea ***
* Conf. dr. Florica POPESCU – Farmacologie
** Asist. univ. Florin-Dan POPESCU – Medicină Internă
*** Doctorand Liviu Ghilencea – Farmacologie, Facultatea de Medicină, Universitatea din Craiova; GlaxoWellcome Romania
Article information. Therapeutical Practice · Ther Pharmacol Clin Toxicol 1997;1(2):98–102 · Article in Romanian with an English abstract
Abstract
Chronic obstructive pulmonary disease (COPD) classification includes subsets of patients with chronic bronchitis, emphysema and asthma. The disease state is caracterised by the presence airllow obstruction, generally progre ssive, that may be accompanied by airway hyperreactivity, and may be partially reversible. This suggests that inhaled short-acting beta-2 agonists (salbutamol), long-acting beta-2 agonists (salmeterol) and corticosteroids (beclomethasone dipropionate, fluticasone propionate) play important increasing roles in the pharmacologic therapy for COPD. *VENT, **SEREVENT, ***BECOTIDE/BECLOFORTE, ****FLIXOTIDE are trademarks of GlaxoWei/come
Keywords: chronic obstructive pulmonary disease (COPD); airflow obstruction; airway hyperreactivity; salbutamol; salmeterol; beclomethasone dipropionate; fluticasone propionate; inhaled route; step-by-step
Cite as: Popescu F, Popescu FD, Ghilencea L. Medicația administrată inhalator în tratamentul bronhopneumopatiei obstructive cronice – actualități. Ther Pharmacol Clin Toxicol. 1997;1(2):98–102.